Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study Authors: Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, Jian Liu Published: 2026 ABSTRACT AbstractBackgroundInetetamab and pyrotinib have shown promising activity in HER2-positive metastatic breast cancer (MBC). However, real-world data on their combination with chemotherapy (IPyC) across different treatment lines remain limited.ObjectivesThis multicenter retrospective study aimed to describe the outcomes associated with a dual HER2-targeting strategy IPyC in HER2-positive MBC across treatment lines in real-world clinical practice.DesignMulticenter retrospective study.MethodsBetween July 2020 and August 2024, 301 patients with HER2-positive MBC from five tertiary centers in China received IPyC until disease progression or unacceptable toxicity. Key outcome measures included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). Cox proportional hazards models were used to identify potential prognostic factors.ResultsThe median IPyC associated PFS and OS for the entire cohort were 12.0 months (95% CI: 10-15) and 33.0 months (95% CI: 28-42), respectively, with an ORR of 50.2% and a CBR of 80.4%. The IPyC associated PFS varied significantly by treatment line (23.0, 17.0, and 6.0 months for first-line, second-line, and ≥third-line, respectively; p<0.001). In first-line setting, baseline lymphovascular invasion (LVI) and multiple metastases were independent prognostic factors, and trastuzumab-naïve patients had a numerically longer median PFS of 27.0 months than those with prior trastuzumab exposure. In second-line setting, patients with secondary resistance to trastuzumab achieved a median PFS of 24.0 months. A new central nervous system (CNS) metastasis incidence was observed in 6.6% (5/76) of patients without baseline CNS metastases in the first-line IPyC treatment setting. The IPyC regimen was associated with manageable toxicity, with grade 3-4 diarrhea (26.2%), neutropenia (16.6%), and leukopenia (12.6%) as the most common adverse events (AEs).ConclusionAs a retrospective descriptive study, our analysis describes the use and outcomes of the IPyC regimen across multiple lines of therapy in HER2-positive MBC, highlighting the need for and supporting the design of prospective studies to evaluate this regimen.Keywords: human epidermal growth factor receptor 2, metastatic breast cancer, inetetamab, pyrotinib, chemotherapy Introduction Approximately 20%-25% of breast cancers exhibit human epidermal growth factor receptor 2 (HER2) overexpression, which is a well-established independent prognostic marker and a critical predictor of the response to anti-HER2 targeted therapies. For HER2-positive metastatic breast cancer (MBC), combination therapy with anti-HER2 agents is the cornerstone of treatment. The CLEOPATRA trial established the docetaxel/trastuzumab/pertuzumab (THP) regimen as the first-line standard. 1 However, only 10.8% of participants had prior adjuvant trastuzumab exposure in CLEOPATRA, whereas most contemporary patients present with prior anti-HER2 therapy, and 30-40% have received dual HER2 blockade or antibody-drug conjugates (ADCs) in the (neo)adjuvant setting. 2 This raises clinical concerns regarding the retreatment efficacy of trastuzumab, as evidenced by the subgroup analysis where THP showed limited additional benefit over TH in prior trastuzumab-treated patients (progression-free survival (PFS) HR 0.62, 95% CI 0.35-1.07; overall survival (OS) HR 0.86, 95% CI 0.51-1.43).1,3 Therefore, there is a pressing need for more effective first-line strategies in the modern treatment landscape. For patients progressing on first-line therapy, ADCs like trastuzumab deruxtecan (T-DXd),4,5 trastuzumab emtansine (T-DM1) 6 and anti-HER2 tyrosine kinase inhibitors (TKIs)7,8 are approved as second-line options. Nonetheless, their application is constrained by several limitations, including potentially severe toxicities (e.g., interstitial lung disease with T-DXd 4 ), financial barriers, and ethnic disparities in safety profiles (e.g., high risk of grade 3-4 thrombocytopenia in Asian patients with T-DM1). 9 Thus, there is a clear need to explore novel anti-HER2 targeted therapies for second- or later-line settings, particularly in ADC-inaccessible patients. The combination of monoclonal antibodies and anti-HER2 TKIs has demonstrated clinically significant advantages over single-agent anti-HER2 therapy in both advanced and neoadjuvant settings.8,10–13 Inetetamab (Cipterbin®) is a novel recombinant humanized anti-HER2 antibody sharing trastuzumab’s binding epitope but with optimized complementarity-determining regions. 14 The phase III HOPES trial has established its efficacy in trastuzumab-naïve MBC patients, where inetetamab combined with vinorelbine achieved superior median PFS (39.1 vs. 14.0 weeks, HR 0.24, p<0.0001) compared to chemotherapy alone. 15 Complementing antibody-based approaches, second-generation anti-HER2 TKIs like pyrotinib, an irreversible pan-HER inhibitor targeting HER1/2/4, have shown notable anti-tumor efficacy and acceptable safety, either used as a monotherapy or in combination with capecitabine in HER2 positive MBC.16–22 Based on clinical data demonstrating that the combination of two anti-HER2 agents with synergistic mechanisms can achieve a more complete inhibition of the HER2 signaling pathway, we hypothesized that combining inetetamab with pyrotinib and chemotherapy (IPyC) could also be beneficial. However, robust real-world evidence describing the outcomes of IPyC across different treatment lines and in patients with varied pretreatment histories remains lacking. Therefore, we conducted this large-scale, real-world study to systematically describe the treatment patterns, outcomes, and safety profile of the IPyC regimen across multiple lines of therapy. We specifically aimed to describe the observed outcomes associated with IPyC when used in the first-line setting, and to explore whether certain patient or disease characteristics were associated with a favorable PFS in later-line therapy, thereby providing real-world descriptive data that may help inform future research addressing these gaps. Materials and methods Study design This multicenter retrospective cohort study was conducted across five tertiary cancer centers in China: Fujian Cancer Hospital; Fujian Provincial Hospital; The First Affiliated Hospital of Xiamen University; Zhangzhou Zhengxing Hospital; and The Third Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine. The study was performed in accordance with the guidelines of the Declaration of Helsinki. The study protocol was approved by the Ethical Committees of Fujian Cancer Hospital, the lead center (Approval No. K2024-534-01). Investigators at all participating centers were informed of the ethical protocol and signed confidentiality agreements ensuring patient medical records/data would be used exclusively for this research. Written informed consent was obtained from all patients. This study was reported in accordance with the STROBE Statement 23 (Supplementary Files). The main inclusion criteria: (I) Female patients aged 18 to 70 years; (II) Histologically confirmed HER2-positive MBC; (III) Eastern Cooperative Oncology Group (ECOG) score ≤2; (IV) Presence of at least one measurable lesion, as defined according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria 24 ; and (V) Patients who received IPyC as metastasis therapy. The main exclusion criteria: (I) Male patients or individuals with prior malignancy; (II) Patients with prior or current enrollment in interventional clinical trials for MBC; (III) Patients who received fewer than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib); and (IV) Patients who were lost to follow-up during the therapeutic process. HER2-positive was defined as follows: 3+ staining intensity by immunohistochemistry (IHC), or IHC 2+ with gene amplification by fluorescence in situ hybridization (FISH). HER2 gene amplification was defined as HER2/CEP17 ratio of ≥2.0 with an average HER2 copy number ≥4.0 signals per cell, or HER2/CEP17 ratio of <2.0 with ≥6.0 HER2 signals per cell. HER2 status was evaluated according to the American Society of Clinical Oncology/College of American Pathologists clinical practice guideline. 25 Patients were considered HER2-positive if either the primary tumor or a metastatic lesion tested positive. 26 Lymphovascular invasion (LVI) was defined as the invasion of tumor cells into definite endothelial-lined spaces (either lymphatic or blood vessels) surrounding invasive carcinoma. Its assessment was conducted by trained pathologists using hematoxylin-eosin-saffron (HES) slides. Specimens with definite LVI were considered as LVI positive. When LVI was rare, uncertain, or detected by IHC only, this was categorized as negative. 27 The treatment lines of anti-HER2 therapy were defined as follows: HER2-positive MBC previously treated (in the adjuvant setting with a disease-free interval (DFI) >12 months) or untreated with anti-HER2 therapy was defined as receiving first-line therapy. MBC previously treated (in the adjuvant setting with a DFI ≤12 months) or that progressed after first-line anti-HER2 therapy was defined as receiving second-line therapy. MBC that progressed after second-line anti-HER2 therapy was defined as receiving third-line therapy. 28 The trastuzumab-sensitive population was defined as follows: advanced stage IV (de novo), no trastuzumab used in the (neo)adjuvant setting, and trastuzumab used in the (neo)adjuvant setting with interval from cessation of trastuzumab to relapse ≥12 months. The resistant population included advanced-stage patients who had failed trastuzumab treatment, and patients in whom trastuzumab was used in the (neo)adjuvant setting with interval from cessation of trastuzumab to relapse was <12 months. The resistant population was divided as follows: primary resistance was defined as (1) the interval from cessation of trastuzumab to relapse was ≤12 months during the adjuvant period or after the discontinuation of trastuzumab; (2) the PFS of first-line trastuzumab in the late stage was <3 months; and secondary resistance was defined as a PFS of trastuzumab in the late stage of >3 months. 29 The anti-HER2 TKI-sensitive population (referring to the definition of trastuzumab sensitivity and resistance) was defined as follows: advanced stage IV (de novo), no anti-HER2 TKI used in the (neo)adjuvant setting, anti-HER2 TKI used in the (neo)adjuvant setting and effective, and an interval between discontinuation of anti-HER2 TKI and recurrence ≥12 months. The resistant population was defined as follows: advanced-stage anti-HER2 TKI treatment failure, anti-HER2 TKI used in the (neo)adjuvant setting, and an interval between discontinuation of anti-HER2 TKI and recurrence <12 months. Therapeutic methods According to the record from the institutional database, patients received intravenous inetetamab (Cipterbin®, 50 mg/bottle; Sunshine Guojian Pharmaceutical) infused at an initial dose of 8 mg/kg and then at a maintenance dose of 6 mg/kg once every 21 days; a single 400 mg dose of pyrotinib (Pyrotinib Maleate Tablets®, 80 mg/tablet; Jiangsu Hengrui Medicine) was given orally every day, and chemotherapy was administered according to the manual until the occurrence of unacceptable adverse events (AEs) or disease progression, the latter of which was evaluated according to the RECIST 1.1 24 every 2 cycles. The guidelines for dose modification due to AEs were as follows: (1) Uncomplicated Grade 3 neutropenia (absolute neutrophil count (ANC) <1000/mm3): restart at the same dose level. (2) Grade 3 neutropenia (ANC <1000/mm3) with a documented infection or fever ≥38.5 °C: 1 dose level reduction. (3) Grade 4 neutropenia (ANC <500/mm3): 1 dose level reduction. (4) Grade 4 thrombocytopenia (platelet count <25,000/mm3): 1 dose level reduction. (5) Nonhematologic toxicity ≥Grade 3, including nausea, vomiting, diarrhea, and hypertension, only if it persists despite optimal medical treatment: 1 dose level reduction. 30 Assessments Patients were generally assessed every 2 cycles during treatment and then every 2 months after the completion of treatment to assess efficacy and safety. Patient data, including medical history, concurrent diseases, age at diagnosis, surgical information, pathological evaluation, and imaging examination results, including computed tomography (CT) scans, positron emission tomography (PET)-CT and bone scans, were retrospectively retrieved. Tumor responses were evaluated by the investigator at each center based on imaging according to RECIST 1.1. 24 Contrast-enhanced magnetic resonance imaging (MRI) was used as the primary modality for central nervous system (CNS) metastases surveillance. Meanwhile, contrast-enhanced computed tomography (CT) was employed as an alternative for patients with contraindications to MRI contrast agents. AEs were assessed according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0). 31 Left ventricular ejection fraction (LVEF) was mainly measured by echocardiography. The decreased LVEF was defined as a value <50% or an absolute reduction of >15% from the same baseline. Regarding the inconsistencies in follow-up data, they would be reviewed and adjudicated by the investigators from each center, with the final decision made by the principal investigator. This study conducted a retrospective analysis of the following endpoints based on available medical records: objective response rate (ORR), clinical benefit rate (CBR), and PFS. Specifically, ORR was calculated as the proportion of patients with a best overall response of complete response (CR) or partial response (PR). CBR was calculated as the proportion of patients who achieved CR, PR, or stable disease (SD) based on imaging and clinical assessment records at approximately 24 weeks after treatment initiation (with a permissible window of ±4 weeks). PFS was calculated as the time from the IPyC treatment start date to the date of first documented disease progression confirmed by imaging or clinical records, or the date of death from any cause. OS was defined as the time from the treatment start date to the date of death from any cause. Statistical analysis Given the relatively limited sample size in subgroups, all subgroup analyses were performed as exploratory only. No adjustment for multiple comparisons was applied, and the findings should be interpreted as descriptive rather than confirmatory. Continuous data were summarized as medians with interquartile ranges (IQRs) or 95% confidence intervals (CIs). Categorical data were presented as frequencies (percentages). Kaplan-Meier survival curves were generated using survival (version 3.5.8) and survminer (version 0.4.9) packages. Univariate Cox proportional hazards regression was conducted to identify potential prognostic factors. Factors with p<0.05 were further included in multivariate Cox regression. Results from univariate and multivariate Cox analyses were visualized as forest plots using forestplot package (version 3.1.3). The cumulative incidence of CNS metastases among patients without baseline brain metastases was estimated using the cumulative incidence function, with death treated as a competing risk. All statistical analyses were performed using R software (version 4.3.3). A two-sided p<0.05 was considered statistically significant. Results Patient characteristics and treatment patterns From July 2020 to August 2024, a total of 377 patients with pathologically confirmed HER2-positive MBC were identified. After excluding 76 patients with insufficient medical records, inadequate follow-up data, ineligible treatment regimens, or other cancer types, 301 patients were included in the final analysis (Figure S1). The median age was 47 years (IQR: 40-53). Of these patients, 75.7% (228/301) had recurrent MBC, and 24.3% (73/301) presented de novo metastatic disease. At baseline, 47.5% (143/301) were hormone receptor (HR)-positive and 84.4% (254/301) were HER2 IHC 3+. Overall, 43.9% (132/301) had multiple metastatic sites (≥3), 72.8% (219/301) had visceral involvement, and 26.9% (81/301) had brain metastases. Notably, among the 81 patients with brain metastases at baseline, 63.0% (51/81) had previously received brain radiotherapy based on the neurological symptoms, imaging findings, systemic disease burden, and patient preference (Table 1). Table 1.Baseline characteristics of total patients.CharacteristicsOverall, n = 301Age at diagnosis, median (IQR), years47.0 (40.0-53.0)ECOG performance status, n (%) 0139 (46.2) 1128 (42.5) 234 (11.3)LVI, n (%) No215 (71.4) Yes86 (28.6)De Novo stage IV, n (%) No228 (75.7) Yes73 (24.3)HER2 status, n (%) IHC 3+254 (84.4) IHC 2+ and FISH+47 (15.6)ER status, n (%) Negative152 (50.5) Positive144 (47.8) Unknown5 (1.7)PR status, n (%) Negative186 (61.8) Positive110 (36.5) Unknown5 (1.7)HR status, n (%) Negative153 (50.8) Positive143 (47.5) Unknown5 (1.7)Number of metastatic sites, n (%) <3169 (56.1) ≥3132 (43.9)Visceral metastasis, n (%) No82 (27.2) Yes219 (72.8)Brain metastasis, n (%) No220 (73.1) Yes81 (26.9)Brain radiotherapy, n (%) No250 (83.1) Yes51 (16.9)Ki67 status, n (%) <3036 (12.0) ≥30265 (88.0)Previous anti-HER2 therapy, n (%) No43 (14.3) Yes258 (85.7)Previous anti-HER2 TKI therapy, n (%) No186 (61.8) Yes115 (38.2)Trastuzumab resistance status, n (%) Primary resistance81 (26.9) Secondary resistance124 (41.2) Sensitive96 (31.9)Anti-HER2 TKI resistance status, n (%) Primary resistance28 (9.3) Secondary resistance83 (27.6) Sensitive190 (63.1)Number of IPyC treatment lines, n (%) First-line96 (31.9) Second-line98 (32.6) Third-line or beyond107 (35.5)ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; IPyC, inetetamab and pyrotinib combined with chemotherapy; IQR, interquartile range; LVI, lymphovascular invasion; PR, progesterone receptor; TKI, tyrosine kinase inhibitor. Baseline characteristics of total patients. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; IPyC, inetetamab and pyrotinib combined with chemotherapy; IQR, interquartile range; LVI, lymphovascular invasion; PR, progesterone receptor; TKI, tyrosine kinase inhibitor. All patients received IPyC, with 31.9% (96/301) as first-line, 32.6% (98/301) as second-line, and 35.5% (107/301) as third-line or beyond (Table 1). Prior to IPyC, 85.7% (258/301) had received anti-HER2 monoclonal antibody-based therapy and 38.2% (115/301) had been treated with anti-HER2 TKIs (Table 1). Vinorelbine (50.5%, 152/301) was the most frequent chemotherapy partner, followed by capecitabine (17.6%, 53/301) and paclitaxel (14.6%, 44/301) (Table S1). Association of treatment line and tumor biology with PFS in the IPyC cohort As of the last follow-up date of July 29, 2025, 59.4% (179/301) of patients had experienced disease progression and 34.6% (104/301) had died. The median follow-up durations were 21.0 months (95% CI: 17.2-24.8) for PFS and 24.0 months (95% CI: 21.0-27.0) for OS. The median PFS was 12.0 months (95% CI: 10-15) (Figure 1(a)), and the median OS was 33.0 months (95% CI: 28-42) (Figure 1(b)). The ORR and CBR were 50.2% and 80.4%, respectively, comprising 7 patients with CR, 144 with PR, and 91 with SD (Figure 1(c)). For 301 patients, univariate (Figure S2) and multivariate Cox (Figure 2(a)) analyses identified LVI, the number of metastatic sites, and IPyC treatment lines as independent prognostic factors for IPyC-associated PFS. As shown in Figure 2(b), patients receiving first-line IPyC had a median PFS of 23.0 months, compared to 17.0 months for second-line and 6.0 months for third-line or beyond (p<0.001). Similarly, patients with multiple metastases or LVI at baseline had shorter PFS than those without these features (Figure 2(c) and (d)). Survival outcomes of all patients with IPyC treatment. (a) Kaplan-Meier curve for PFS of all patients. (b) Kaplan-Meier curve for OS of all patients. (c) Donut chart summarizing the ORR and CBR of all patients. CBR, clinical benefit rate; CR, complete response; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. Potential prognostic factors for PFS of all patients with IPyC treatment. (a) Forest plot of multivariate Cox regression analysis for PFS; (b) Kaplan-Meier curve for PFS stratified by the number of IPyC treatment lines; (c) Kaplan-Meier curve for PFS stratified by baseline multiple metastases status; (d) Kaplan-Meier curve for PFS stratified by baseline LVI status. ER, estrogen receptor; IPyC, inetetamab and pyrotinib combined with chemotherapy; LVI, lymphovascular invasion; mPFS, median progression-free survival; PR, progesterone receptor. Outcomes and potential prognostic factors for first-line of IPyC therapy Among the 96 patients who had received IPyC as first-line therapy for advanced disease, the observed median PFS was 23.0 months. Univariate (Figure S3) and multivariate (Figure 3(a)) Cox regression analyses identified LVI and multiple metastases at baseline as independent prognostic factors for PFS. Patients without LVI had a median PFS of 36.0 months (Figure 3(b)), whereas in those without multiple metastatic sites, the median PFS was not reached at the time of analysis (Figure 3(c)). Potential prognostic factors for PFS of patients with first-line IPyC treatment. (a) Multivariate Cox regression analysis for PFS in the first-line setting; (b) Kaplan-Meier curve for PFS stratified by baseline LVI status; (c) Kaplan-Meier curve for PFS stratified by baseline multiple metastases status; (d) Kaplan-Meier curve for PFS stratified by prior anti-HER2 therapy; (e) Kaplan-Meier curve for PFS stratified by type of prior anti-HER2 regimen. H, trastuzumab; HER2, human epidermal growth factor receptor 2; HP, trastuzumab and pertuzumab; IPyC, inetetamab and pyrotinib combined with chemotherapy; LVI, lymphovascular invasion; mPFS, median progression-free survival. Prior to IPyC, 55.2% (53/96) of patients had received anti-HER2 therapy. As shown in Figure 3(d), patients without prior therapy had a median PFS of 27.0 months, compared with the 19.0 months in those with prior anti-HER2 treatment. Further analysis in patients who had received prior anti-HER2 therapy revealed that type of prior regimen (trastuzumab alone (H) vs. trastuzumab plus pertuzumab (HP)) had no discernible association with PFS following subsequent first-line IPyC (with median PFS of 19.0 months in both subgroups, Figure 3(e)). Outcomes and potential prognostic factors for later-lines of IPyC therapy A total of 98 patients who experienced progressive disease after first-line anti-HER2 therapy received IPyC as second-line treatment, with a median PFS of 17.0 months. Patients were stratified according to two key factors: prior trastuzumab-resistance status (primary vs. secondary) and prior anti-HER2 TKI resistance/sensitivity status (sensitive, primary resistant, or secondary resistant). These variables, together with baseline characteristics, were subsequently included in univariate (Figure S4) and multivariate (Figure 4(a)) Cox analyses. Potential prognostic factors for PFS of patients with second-line IPyC treatment. (a) Multivariate Cox regression analysis for PFS in the second-line setting; (b) Kaplan-Meier curve for PFS stratified by multiple metastases status; (c) Kaplan-Meier curve for PFS stratified by trastuzumab resistance status; (d) Kaplan-Meier curve for PFS stratified by prior anti-HER2 TKI response; (e) Kaplan-Meier curve for PFS in a subgroup analysis combining baseline multiple metastases status and trastuzumab resistance. HER2, human epidermal growth factor receptor 2; IPyC, inetetamab and pyrotinib combined with chemotherapy; mPFS, median progression-free survival; TKI, tyrosine kinase inhibitor. In multivariate analysis for this subgroup (Figure 4(a)), the presence of multiple metastases and sensitivity/resistance status to prior trastuzumab/anti-HER2 TKI were independently associated with PFS. Patients without baseline multiple metastatic sites had a median PFS of 24.0 months with second-line IPyC (Figure 4(b)). Among trastuzumab-resistant patients, those with secondary resistance had a significantly longer PFS than patients with primary resistance (24.0 vs 8.0 months, Figure 4(c)). Primary resistance to anti-HER2 TKIs was associated with the worst PFS, while no significant difference in PFS was observed between the secondary resistance and anti-HER2 TKI-sensitive groups (Figure 4(d)). Further analysis showed that a subset of patients with neither multiple metastases nor primary trastuzumab resistance had a median PFS of 28.0 months, which was numerically comparable with the 27.0 months observed in the first-line, anti-HER2-naïve patients (Figure 4(e)). For the 107 patients who received IPyC as third- or later-line treatment, the median PFS was 6.0 months. In this setting, age, primary/secondary resistance to trastuzumab and sensitivity/resistance to anti-HER2 TKI were identified as independent factors associated with PFS of IPyC treatment (Figure S5, Figure 5). As illustrated in Figure 5(c), patients sensitive to anti-HER2 TKI had the longest PFS of 14.0 months, whereas those with primary resistance to anti-HER2 TKI had the shortest PFS of 4.0 months. Although the PFS of patients with secondary resistance to trastuzumab was only 8.0 months, it was still significantly longer than that of patients with primary resistance (Figure 5(d)). Potential prognostic factors for PFS of patients with third-line or beyond IPyC treatment. (a) Multivariate Cox regression for PFS in the third-line or beyond setting. (b) Kaplan-Meier curve for PFS stratified by age. (c) Kaplan-Meier curve for PFS stratified by anti-HER2 TKI resistance status. (d) Kaplan-Meier curve for PFS stratified by trastuzumab resistance status. HER2, human epidermal growth factor receptor 2; IPyC, inetetamab and pyrotinib combined with chemotherapy; LVI, lymphovascular invasion; mPFS, median progression-free survival; TKI, tyrosine kinase inhibitor. Description of CNS metastasis progression patterns At baseline, 26.9% (81/301) of patients presented with CNS metastases. Following the treatment with the IPyC regimen, new CNS metastases (defined as radiographic or cytological confirmation of new CNS lesions following treatment initiation) were observed in 39.5% (32/81) of those with baseline brain metastases versus 10.0% (22/220) of those without (Figure 6(a)). CNS metastasis progression patterns in IPyC cohort. (a) Sankey diagram showing new CNS metastasis progression stratified by baseline CNS involvement status (with vs. without). (b) Cumulative incidence curves for new CNS metastases in patients without baseline CNS involvement. (c) Bar chart comparing the incidence of new CNS metastases in patients without baseline CNS metastasis at 12 and 24 months. (d) Time to new CNS progression from IPyC initiation in patients without baseline CNS metastases. CNS, central nervous system; IPyC, inetetamab and pyrotinib combined with chemotherapy; mPFS, median progression-free survival. Among the 96 first-line patients, 20 had CNS metastases at baseline. Of these 20 patients, 13 received radiotherapy and 4 developed CNS progression (30.8%). The remaining 7 did not receive radiotherapy, of whom 3 developed CNS progression (42.9%). The other 76 patients (79.2%, 76/96) had no CNS metastases at baseline, and 5 (6.6%, 5/76) subsequently developed new CNS metastases after IPyC initiation. For patients without baseline CNS metastases, the cumulative incidence of new CNS metastases after accounting for death as a competing risk varied by treatment line. In the first-line setting, the cumulative incidence was 2.9% at 12 months and 11.9% at 24 months. In the second-line setting, the cumulative incidence was 10.1% at 12 months and 18.0% at 24 months. For patients receiving third-line or beyond therapy, the cumulative incidence was 13.5% at 12 months and 18.0% at 24 months (Figure 6(b) and (c)). The median time to new CNS progression during IPyC treatment was 15 months for first-line patients, 12 months for second-line patients, and 5 months for those treated beyond the second line (Figure 6(d)). Safety The safety profile of the IPyC regimen was associated with manageable toxicity, with AEs predominantly graded 1-2 in severity. The most frequent treatment-related grade 3-4 toxicities were primarily hematologic and gastrointestinal, with diarrhea (26.2%), neutropenia (16.6%), and leukopenia (12.6%). All other grade ≥3 AEs occurred at frequencies below 4%. Treatment modifications due to AEs included dose reductions in 57 patients (18.9%) with persistent diarrhea, 20 (6.6%) with neutropenia, 11 (3.7%) with leukopenia, and 2 (0.7%) with thrombocytopenia. Detailed safety data are summarized in Table 2. Among patients with available LVEF data, the incidence of LVEF decline was 1.8% (4/227; first-line: 1.3%, 1/77; second-line: 1.5%, 1/66; third-line or beyond: 2.4%, 2/84). Table 2.Incidence of AEs.AEsAny grade (n, %)Grade 3-4 (n, %)Diarrhea213 (70.8)79 (26.2)Neutropenia154 (51.2)50 (16.6)Nausea123 (40.9)8 (2.7)Leukocytopenia121 (40.2)38 (12.6)Anemia106 (35.2)7 (2.3)Peripheral edema77 (25.6)12 (4.0)Asthenia76 (25.2)1 (0.3)Pain67 (22.3)3 (1.0)Vomiting66 (21.9)5 (1.7)Thrombocytopenia46 (15.3)5 (1.7)Fever21 (7.0)2 (0.7)Infusion related reaction18 (6.0)2 (0.7)Arrhythmia13 (4.3)3 (1.0)Myocardial ischemia10 (3.3)3 (1.0)Tachypnoea6 (2.0)2 (0.7)AEs, adverse events. Incidence of AEs. AEs, adverse events. Three patients discontinued treatment due to grade 4 AEs: one had a paclitaxel-related infusion reaction (resolved with epinephrine, fluids, and antiallergics); one with prior cardiac history developed myocardial ischemia from medication nonadherence due to gastrointestinal toxicity (improved after thrombolytic therapy but subsequently discontinued treatment); and one developed cardiac arrhythmia caused by high-degree atrioventricular block after two cycles of the IPyC regimen (possibly IPyC-related, recovered after permanent pacemaker implantation). Discussion To our knowledge, this is a large real-world study of the IPyC regimen in HER2-positive MBC. As a retrospective, single-arm descriptive study, it provides real-world outcome data for IPyC across treatment lines, particularly in a patient population with substantial prior anti-HER2 exposure (55.2%). Our findings describe the observed differences by treatment line, resistance phenotype, and CNS status, offering the preliminary evidence to inform future prospective studies. In the overall cohort, treatment line emerged as an important prognosis factor. Importantly, line of therapy is not merely an indicator of treatment sequence; it also correlates with disease burden, prior anti-HER2 exposure and intrinsic resistance mechanisms. Patients receiving first-line IPyC had an observed median PFS of 23.0 months. This finding provides the real-world data of the IPyC regimen in a patient population where the majority (55.2%) had prior anti-HER2 exposure, a profile that differs from earlier trial populations.32,33 These observations reflect a shift in modern clinical practice, with most patients now being exposed to anti-HER2 agents in the (neo)adjuvant setting prior to a MBC diagnosis, which may increase the risk of drug resistance and worsen prognosis. 34 In the first-line setting, patients with prior anti-HER2 exposure had a numerically shorter PFS than those without (19.0 vs 27.0 months), although this difference did not reach statistical significance. This is likely due to the limited sample size of the subgroup. Notably, the type of prior regimen (trastuzumab alone vs. trastuzumab plus pertuzumab) showed no discernible association with PFS, suggesting that the presence of prior HER2-directed exposure, rather than the specific regimen, may influence subsequent IPyC outcomes. The IPyC regimen was associated with a median PFS of 17.0 months in second-line settings. Patients with secondary trastuzumab resistance had a significantly longer PFS than those with primary resistance (24.0 vs. 8.0 months). These subgroup comparisons were not adjusted for multiplicity and require prospective confirmation. One possible explanation is that tumors with secondary resistance retain HER2 addiction, as these patients initially responded to anti-HER2 therapy. In contrast, primary resistance frequently involves bypass signaling through PIK3CA/PTEN aberrations or p95HER2 expression, along with a more aggressive tumor phenotype.35–40 Persistent HER2 amplification in secondary resistance may also sustain sensitivity to subsequent HER2-directed therapy.37,41 Additional translational studies are needed to clarify these resistance mechanisms in the context of IPyC treatment. When examined by treatment line, prognostic factors differed across lines. In first-line therapy, outcomes were primarily associated with baseline tumor burden (e.g., LVI, 27 multiple metastases 42 ). This association aligns with established evidence that inherent tumor biology is an important contributor to outcomes for patients initiating first-line metastatic treatment. When IPyC was used in second-line, the nature of prior trastuzumab resistance became notable correlative factor. The observed better outcomes in patients with secondary versus primary suggest that resistance phenotype rather than progressive disease alone, may correlate with responsiveness to subsequent anti-HER2 regimens.43,44 This prognostic distinction was also apparent in later lines (≥3 lines), where primary resistance to prior anti-HER2 TKIs was associated with the poorest outcomes, highlighting a subset of heavily pretreated patients with a high unmet need for novel therapeutic strategies. Given the exploratory nature of subgroup analysis and the limited sample size, all these findings should be interpreted as hypothesis-generating and require validation in larger prospective cohorts. Inetetamab has an identical Fab domain to trastuzumab but with two amino acid substitutions in the constant region of the heavy chain Fc domain: aspartic acid (D359) and leucine (L361) replace the glutamate (E359) and methionine (M361) residues present in trastuzumab. 45 Inetetamab exhibits HER2 binding affinity, antiproliferative activity, protein folding profiles, and thermal stability comparable to those of trastuzumab, 46 while its two Fc-region amino acid substitutions specifically enhance antibody-dependent cellular cytotoxicity (ADCC).47–50 In the phase III HOPES study, inetetamab plus vinorelbine significantly prolonged median PFS compared with vinorelbine alone in patients without prior anti-HER2 therapy (39.1 weeks vs. 14.0 weeks). 15 Subgroup analysis of HOPES study indicated that inetetamab as first-line treatment for HER2-positive advanced breast cancer demonstrated a median PFS of 11.1 months and an ORR of 61.5%. 45 A real-world study of inetetamab-based regimens further supported its role as an effective therapeutic option for HER2-positive MBC. As reported in the aforementioned study, patients achieved a median PFS of 22.2 months, 12.9 months, and 4.8 months in the first-line, second-line, and third-line or beyond settings, respectively. 51 Pyrotinib, a small-molecule anti-HER2 TKI, targets the intracellular tyrosine kinase domain of HER2, effectively inhibiting downstream signaling even in the context of truncated HER2 receptors or other adaptive changes that confer resistance to monoclonal antibodies like trastuzumab.52–55 Concurrently, Yang et al. reported that in patients resistant to the combination regimen of docetaxel, carboplatin, trastuzumab, and pertuzumab, cancer-associated fibroblasts form a protective barrier that hinders immune cell infiltration. The combination regimen of pyrotinib, inetetamab, docetaxel, and carboplatin was shown to disrupt this fibroblastic barrier, thereby enhancing immune cell access and reversing treatment resistance. 56 Combined with the enhanced ADCC effect conferred by the engineered Fc fragment of inetetamab, these complementary mechanisms may help explain the outcomes observed with IPyC regimen in this patient population. The combination regimen of IPyC showed manageable toxicity. Consistent with previous reports of similar regimens,45,57 hematological AEs predominantly manifested as leukopenia and neutropenia. They were primarily attributed to concomitant chemotherapy, and could be effectively managed with granulocyte colony-stimulating factor (G-CSF). 58 For the non-hematological toxicities, the most common AE was diarrhea (70.8%). It was predominantly associated with anti-HER2 TKI of pyrotinib, with grade 3 diarrhea occurring in 22.6% of patients. Prior studies have reported that grade 3 treatment-related diarrhea occurred in approximately 31% of patients receiving pyrotinib plus capecitabine, in 22.7% of those receiving pyrotinib plus vinorelbine, and in 22.5% of those receiving with pyrotinib monotherapy.7,21,59 Diarrhea was generally preventable and reversible through dietary modification and anti-diarrhea treatment with glutamine, Bifidobacterium, and montmorillonite powder. Furthermore, real-world evidence indicates that cardiotoxicity manifesting as LVEF decline is uncommon among patients receiving inetetamab-based regimens, with reported incidence ranging from approximately 0% to 2%.60,61 Similar to these findings, the incidence of decreased LVEF was 1.8% in the overall cohort of the present study. This study has several limitations. First, this retrospective analysis lacked a comparator arm, and information bias from heterogeneous documentation and residual confounding cannot be fully eliminated. Second, most participating institutions were in Fujian Province of China. This limits the generalizability of the overall Chinese population. Additionally, the extended enrollment period may have introduced temporal bias from evolving treatment patterns. Third, brain MRI surveillance was not standardized across centers, potentially leading to underdetection of asymptomatic CNS metastases. Despite a competing risk analysis, the absence of a comparator precludes any conclusion of a CNS-protective effect. Finally, OS data remain immature and will be reported separately upon maturation. Furthermore, inetetamab and pyrotinib are currently available primarily in China, constraining international applicability. Conclusion Despite these limitations, this large-scale real-world analysis provides descriptive data on the outcomes associated with the IPyC regimen and identifies potential prognostic factors in HER2-positive MBC. A prospective, multicenter, phase II study (NCT05621434) evaluating first-line IPyC based on these observations has been launched. Large-scale randomized trials are still warranted to further confirm its long-term efficacy. Supplemental material Supplemental material - Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study Supplemental material for Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study by Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, and Jian Liu in Therapeutic Advances in Medical Oncology. Supplemental material - Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study Supplemental material for Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study by Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, and Jian Liu in Therapeutic Advances in Medical Oncology. Acknowledgments We thank the patients who participated in this study and the oncologists, pathologists, and nursing staff for their support. Author contributions: Fan Wu: Conceptualization; Formal analysis; Writing – Original Draft; Investigation; Resources. Cailing Lin: Investigation; Resources. Zhiwu Lin: Investigation; Resources. Qingmo Yang: Investigation; Resources. Xiuping Wu: Investigation; Resources. Biyin Chen: Investigation; Resources. Nani Li: Validation; Data curation. Ruxue Zhang: Validation; Data curation. Xiufeng Wu: Validation; Data curation. Weiwei Huang: Validation; Data curation. Xinhua Chen: Validation; Data curation. Yi Hong: Validation; Data curation. Kan Chen: Validation; Data curation. Jian Liu: Conceptualization; Investigation; Resources; Writing – Review & Editing. Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The current study was sponsored by the Fujian Provincial Health Technology Project 2022GGB012. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Supplemental material: Supplemental material for this article is available online. ORCID iD Jian Liu https://orcid.org/0009-0009-7819-6801 Ethical considerations The study was performed in accordance with the guidelines of the Declaration of Helsinki (as revised in 1975). The study protocol was approved by the Ethical Committees of Fujian Cancer Hospital, the lead center (Approval No. K2024-534-01). Investigators at all participating centers were informed of the ethical protocol and signed confidentiality agreements ensuring patient medical records/data would be used exclusively for this research. Consent to participate Written informed consent was obtained from all patients. Data Availability Statement The data used and/or analyzed in this study is available from the corresponding author on reasonable request.* References Associated Data Supplementary Materials Supplemental material - Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study Supplemental material for Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study by Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, and Jian Liu in Therapeutic Advances in Medical Oncology. Supplemental material - Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study Supplemental material for Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study by Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, and Jian Liu in Therapeutic Advances in Medical Oncology. Data Availability Statement The data used and/or analyzed in this study is available from the corresponding author on reasonable request.*